Considering the oncogenic role of CDK5 in cancer, targeting the ATP binding of CDK5 and CDK5-p35 interaction is currently the two major strategies to suppress CDK5 activity, which has been used in preclinical trials of drugs for several types of tumors (Table 4) [114–116]. The gene discussed is CDK5R1; the disease is cancer.